Trial Profile
Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Renal failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACTION
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.
- 08 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Sep 2020.
- 11 Mar 2020 Status changed from recruiting to active, no longer recruiting.